For example, Li et al. [25] report a significantly longer postoperative recurrence-free rate in patients with bladder cancer with either high DR4 or DR5 expression, than in those with low expression of both receptors identified during a 10-year follow-up. This evidence concerns the gene TNFRSF10A and urinary bladder carcinoma.